Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Forventet)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Bijan Najafi, PhD
- Telefonnummer: 7137987536
- E-post: najafi.bijan@gmail.com
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85724
- Rekruttering
- University of Arizona
-
Ta kontakt med:
- Bijan S Najafi, PhD
- Telefonnummer: 713-798-0477
- E-post: najafi.bijan@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Diagnosis of:
- diabetes
- cancer
- multiple sclerosis
- arthritis
- Parkinson's disease
- cognitive disorders
- brain injury
- frailty
- stroke
Exclusion Criteria:
- conditions not related to specific disorders affecting balance and gait
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Exergame
inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback.
The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
|
Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e.
balancing on single leg) using wearable sensors technology (Exergaming) equipment).
Subjects will perform these exercises for 4-6 weeks, twice per week.
The duration of exercise per session is anticipated to be 30-45 minutes.
Andre navn:
|
|
Aktiv komparator: Home based balance training
The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback.
Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
|
Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks.
The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Balance
Tidsramme: 4-6 weeks
|
Balance will be quantified by measuring area of sway of center of mass (with unit of cm2) during quite standing according to Romberg's protocol and using validated instrument (BalanSens, Biosensics, MA, USA)
|
4-6 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in gait Speed
Tidsramme: 4-6 weeks
|
Gait Speed (with unit of m/sec) will be measured using validated wearable technology (LEGSys, Biosensics, MA, USA) and during walking with habitual and fast speed walking
|
4-6 weeks
|
|
Change in Stride length
Tidsramme: 4-6 weeks
|
Stride Length (with unit of meter) will be measured using validated wearable technology (LEGSys, Biosensics, MA, USA) and during walking with habitual and fast speed walking
|
4-6 weeks
|
|
Change in Stride time
Tidsramme: 4-6 weeks
|
Stride time (with unit of second) will be measured using validated wearable technology (LEGSys, Biosensics, MA, USA) and during walking with habitual and fast speed walking
|
4-6 weeks
|
|
Change in number of walking steps per day
Tidsramme: 4-6 weeks
|
Average of walking steps (no unit) per day will be measured during 48 hours of daily physical activity monitoring using a validated wearable sensor technology (PAMSys, Biosensics, MA, USA)
|
4-6 weeks
|
|
Change in average of walking bout
Tidsramme: 4-6 weeks
|
Daily average of walking bout (continuous walking without stop, with unit of steps) will be measured over 48 hours monitoring of physical activity using a validated wearable sensor technology (PAMSys, Biosensics, MA, USA)
|
4-6 weeks
|
|
Change in average of standing bout
Tidsramme: 4-6 weeks
|
Daily average of standing bout (continuous standing without changing in posture with unit of seconds) will be measured over 48 hours monitoring of physical activity using a validated wearable sensor technology (PAMSys, Biosensics, MA, USA)
|
4-6 weeks
|
|
Change in average of longest walking bout
Tidsramme: 4-6 weeks
|
Daily average of longest walking bout (longest continuous walking without stop per day, with unit of steps) will be measured over 48 hours monitoring of physical activity using a validated wearable sensor technology (PAMSys, Biosensics, MA, USA)
|
4-6 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Forventet)
Primær fullføring
Studiet fullført (Forventet)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Sykdommer i immunsystemet
- Demyeliniserende autoimmune sykdommer, CNS
- Autoimmune sykdommer i nervesystemet
- Demyeliniserende sykdommer
- Autoimmune sykdommer
- Sår og skader
- Nevrokognitive lidelser
- Parkinsonlidelser
- Basal ganglia sykdommer
- Bevegelsesforstyrrelser
- Synukleinopatier
- Nevrodegenerative sykdommer
- Kraniocerebralt traume
- Traumer, nervesystemet
- Multippel sklerose
- Parkinsons sykdom
- Hjerneskader
- Kognisjonsforstyrrelser
Andre studie-ID-numre
Andre studie-ID-numre
- 1409482826
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .